BioCentury
ARTICLE | Company News

KS Biomedix, MedPharm in antibody deal

May 29, 2001 7:00 AM UTC

KS Biomedix (LSE:KSB) will develop with MedPharm (London, U.K.) a solid suppository dosage form of its KSB304 antibody to treat ulcerative colitis. KSB304 targets the colonic epithelial protein, which...